Gynecology

ACOG, SWHR, and WFRC are calling on Congress to invest $20B over 10 years to close the women's health gap.

Kate McLean, MD, describes how newly defined bacterial vaginosis subtypes could validate patient symptoms and inform treatment.

The SELF-GYN1 trial found that at-home transvaginal ultrasonography met diagnostic quality standards in 96.2% of scans and was significantly preferred by participants over in-clinic imaging.

89.6% of women tested with Xpert Xpress MVP received appropriate treatment within 24 hours vs 51.9% with usual care.

Daré Bioscience has launched Flora Sync LF5, a non-prescription vaginal probiotic capsule containing Limosilactobacillus fermentum LF5.

A reader-driven look at the 10 most-viewed articles on Contemporary OB/GYN from the first half of 2026, spanning FDA decisions, clinical research, and emerging treatments across menopause, contraception, endometriosis, and pelvic health.

A recap of the top FDA news stories covered by Contemporary OB/GYN in Q2 2026, spanning cervical cancer screening, menopause therapeutics, and antibiotic treatment for urinary tract infections.

Nishita Pondugula, MD, MS, explains her session surrounding associations of gestational weight gain and hypertensive pregnancy disorders with prepregnancy GLP-1 exposure.

Elle Kielar Grevstad, PhD, explains how a 2-MDM panel detected endometrial cancer in self-collected vaginal fluid with 96% sensitivity and 82% specificity, according to a marker reduction study published in Gynecologic Oncology.

Jessia Gaulton, MD, MPH, speaks to knowledge and gaps surrounding the menopause transition and mental health associations, while highlighting new Menopause Hub resources from FamilyWell Health.

Backed by phase 3 data showing an overall success rate of 58.5% versus 60.2% for IV imipenem-cilastatin, tebipenem HBr has been approved by the FDA as the first oral carbapenem antibiotic for the treatment of complicated urinary tract infections in the US.

Mark Simon, MD, MMM, highlights the role of the OB hospitalist as a collaborative partner who can initiate rapid treatment for hypertensive crises in the hospital setting.

Susan Loeb-Zeitlin, MD, FACOG, breaks down the recently-updated ACOG guidance related to postmenopausal bleeding.

Melissa Loseke, DO, highlighted evidence that testosterone therapy in women may improve energy, mood, cognition, and cardiometabolic markers beyond sexual function.

The FDA has approved Wockhardt’s cefepime and zidebactam, a novel intravenous antibiotic that targets multiple penicillin-binding proteins to treat adults with complicated urinary tract infections.

These are the top 5 headlines you might have missed from May 2026.

Esther H. Chung, MD, discusses how earlier fertility education, emotional screening, and structured referrals can improve patient experiences and outcomes in infertility care.

David Shalowitz explains why experts now recommend a dual approach for most patients with postmenopausal bleeding due to limitations in ultrasound accuracy.

Earlier initiation of conservative therapies may improve outcomes and reduce the need for advanced treatment in stress urinary incontinence.

Cervical cancer screening increased by 2.2 percentage points after program implementation, though 12.6% of eligible individuals received testing kits.

Sameena Rahman, MD, FACOG, asserts that the word "metabolic" in PMOS should fundamentally change clinical perceptions, transforming it from a GYN issue into a universally treated systemic condition.

Sameena Rahman, MD, FACOG, highlights that renaming PCOS to PMOS is vital for recognizing the condition as a systemic metabolic disorder rather than a simple ovarian issue.

The vaginal insert will be available starting May 19, 2026.

According to a publication in The Lancet, a multistep process was used to generate a new name to avoid misleading references to ovarian cysts while accurately reflecting the condition's diverse features.

Elizabeth Alderman, MD, and Julie Samuels explain new research detailing what data exists for period poverty in high-income countries, as well as the lack of data on established interventions.